Initial evaluation of the antitumour activity of KGP94, a functionalized benzophenone thiosemicarbazone inhibitor of cathepsin L

European Journal of Medicinal Chemistry

Volumn 58, Issue , 2012, Pages 568-572

  Chavarria, Gustavo E ^a   Horsman, Michael R ^b   Arispe, Wara M ^a   Kishore Kumar, G D ^a   Chen, Shen En ^a   Strecker, Tracy E ^a   Parker, Erica N ^a   Chaplin, David J ^c   Pinney, Kevin G ^a   Trawick, Mary Lynn ^a  

^a BAYLOR UNIVERSITY   (United States)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c OXiGENE Inc   (United States)

Author keywords

Benzophenone thiosemicarbazone; Cathepsin L inhibitor; Cell invasion; Mammary mouse model; MDA MB 231 breast cancer cells; Time dependent inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; CARBONYL DERIVATIVE; CATHEPSIN L; COLLAGEN TYPE 1; CYSTEINE; CYSTEINE PROTEINASE INHIBITOR; KGP 94; THIOCTIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; COVALENT BOND; CYTOTOXICITY; DRUG INHIBITION; ENZYME ACTIVE SITE; FEMALE; GROWTH RETARDATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; KINETICS; MOUSE; NONHUMAN; STEADY STATE; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CATHEPSIN L; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYSTEINE PROTEINASE INHIBITORS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED STRAINS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; THIOSEMICARBAZONES; THIOUREA;

EID: 84869145551     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.10.039     Document Type: Article

References (26)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA. Cancer J. Clin. 61 2011 69 90
2. C.L. Chaffer, and R.A. Weinberg A perspective on cancer cell metastasis Science 331 2011 1559 1564
3. J.M. Lankelma, D.M. Voorend, T. Barwari, J. Koetsveld, A.H. Van der Spek, A.P.N.A. De Porto, G.V. Rooijen, and C.J.F. Van Noorden Cathepsin L, target in cancer treatment? Life Sci. 86 2010 225 233
4. B. Goulet, L. Sansregret, L. Leduy, M. Bogyo, E. Weber, S.S. Chauhan, and A. Nepveu Increased expression and activity of nuclear cathepsin L in cancer cells suggests a novel mechanism of cell transformation Mol. Cancer Res. 5 2007 899 907
5. G. Leto, M.V. Sepporta, M. Crescimanno, C. Flandina, and F.M. Tumminello Cathepsin L in metastatic bone disease: therapeutic implications Biol. Chem. 391 2010 655 664
6. E.M. Duncan, T.L. Muratore-Schroeder, R.G. Cook, B.A. Garcia, J. Shabanowitz, D.F. Hunt, and C.D. Allis Cathepsin L proteolytically processes histone H3 during mouse embryonic stem cell differentiation Cell. 135 2008 284 294
7. N. Katunuma Structure-based development of specific inhibitors for individual cathepsins and their medical applications Proc. Jpn. Acad. B. Phys. 87 2011 29 39
8. T. Schirmeister, and U. Kaeppler Non-peptidic inhibitors of cysteine proteases Mini. Rev. Med. Chem. 3 2003 361 373
9. G.D.K. Kumar, G.E. Chavarria, A.K. Charlton-Sevcik, W.M. Arispe, M.T. MacDonough, T.E. Strecker, S.-E. Chen, B.G. Siim, D.J. Chaplin, M.L. Trawick, and K.G. Pinney Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors Bioorg. Med. Chem. Lett. 20 2010 1415 1419
10. G.D.K. Kumar, G.E. Chavarria, A.K. Charlton-Sevcik, G.K. Yoo, J. Song, T.E. Strecker, B.G. Siim, D.J. Chaplin, M.L. Trawick, and K.G. Pinney Functionalized benzophenone, thiophene, pyridine, and fluorine thiosemicarbazone derivatives as inhibitors of cathepsin L Bioorg. Med. Chem. Lett. 20 2010 6610 6615
11. M.L. Trawick, K.G. Pinney, D.J. Chaplin, M.R. Horsman, G.E. Chavarria, W.M. Arispe, and G.D.K. Kumar Development and initial evaluation of the antitumour activity of a functionalized benzophenone thiosemicarbazone inhibitor of cathepsin L Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL 2011 AACR Philadelphia (PA) Abstract nr 1416
12. D.R. Sudhan, and D.W. Siemann Abrogation of prostate cancer cell metastatic phenotype by cathepsin-L inhibition Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL 2011 AACR Philadelphia (PA) Abstract nr 1422
13. O. Ishibashi, Y. Mori, T. Kurokawa, and M. Kumegawa Breast cancer cells express cathepsins B and L but not cathepsins K or H Cancer Biochem. Biophys. 17 1999 69 78
14. R. Colella, T. Jackson, and E. Goodwin Matrigel invasion by the prostate cancer cell lines, PC3 and DU145, and cathepsin L+B activity Biotech. Histochem. 79 2004 121 127
15. M.R. Horsman, E. Ehrnrooth, M. Ladekarl, and J. Overgaard The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumours Int. J. Radiat. Oncol. 42 1998 895 898
16. M.R. Horsman, and R. Murata Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response Int. J. Radiat. Oncol. 57 2003 1047 1055
17. P.P. Shah, M.C. Myers, M.P. Beavers, J.E. Purvis, H. Jing, H.J. Grieser, E.R. Sharlow, A.D. Napper, D.M. Huryn, B.S. Cooperman, A.B. Smith III, and S.L. Diamond Kinetic characterization and molecular docking of a novel, potent, and selective slow-binding inhibitor of human cathepsin L Mol. Pharmacol. 71 2008 34 41
18. C. Dash, V. Vathipadiekal, S.P. George, and M. Rao Slow-tight binding inhibition of xylanase by an aspartic protease inhibitor J. Biol. Chem. 277 2002 17978 17986
19. R.A. Copeland Slow binding inhibitors R.A. Copeland, Slow Binding Inhibitors, Evaluation of Enzyme Inhibitors in Drug Discovery 2005 John Wiley & Sons, Inc. New Jersey 141 177
20. J.P. Falqueyret, R.M. Oballa, O. Okamoto, G. Wesolowski, Y. Aubin, R.M. Rydzewski, P. Prasit, D. Riendeau, S.B. Rodan, and M.D. Percival Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L J. Med. Chem. 44 2001 94 104
21. K.G. Vogel, M. Paulsson, and D. Heinegård Specific inhibition of type I and type II collagen fibrillogenesis by the small proteoglycan of tendon Biochem. J. 223 1984 587 597
22. Z. Li, Y. Yasuda, W. Li, M. Bogyos, N. Katz, R.E. Gordon, G.B. Fields, and D. Brömme Regulation of collagenase activities of human cathepsins by glycosaminoglycans J. Biol. Chem. 279 2004 5470 5479
23. H. Kirschke, A.A. Kembhavi, P. Bohley, and A.J. Barrett Action of rat liver cathepsin L on collagen and other substrates Biochem. J. 201 1982 367 372
24. J. Selent, J. Kaleta, Z. Li, G. Lalmanach, and D. Brömme Selective inhibition of the collagenase activity of cathepsin K J. Biol. Chem. 282 2007 16492 16501
25. J.E. Koblinski, M. Ahram, and B.F. Sloane Unraveling the role of proteases in cancer Clin. Chim. Acta 291 2000 113 135
26. PDB ID: 1ICF G. Guncar, G. Pungercic, I. Klemencic, V. Turk, and D. Turk Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S EMBO J. 18 1999 793 803 10.2210/pdb1icf/pdb